Testing MitoQ to Improve Platelet Function in Sickle Cell Anemia
Effect of MitoQ on Platelet Function and Reactive Oxygen Species (ROS) Generation in Patients With Sickle Cell Anemia
This study is testing if a new antioxidant called MitoQ can help improve blood platelet function and overall health in people with sickle cell anemia.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Pittsburgh Academic / other |
| Locations | 5 sites (Pittsburgh, Pennsylvania and 4 other locations) |
| Trial ID | NCT04109820 on ClinicalTrials.gov |
What this trial studies
This research investigates the effects of MitoQ, an antioxidant, on platelet function and reactive oxygen species generation in patients with sickle cell anemia. The study aims to determine if MitoQ can reduce platelet activation and improve vascular health in these patients. Participants will receive MitoQ orally for 14 days, with assessments of platelet count, hemolytic markers, and blood pressure taken before and after treatment. The trial includes both sickle cell patients and healthy controls for comparison.
Who should consider this trial
Good fit: Ideal candidates are African American adults aged 18 and older with a diagnosis of sickle cell anemia.
Not a fit: Patients who are pregnant, have hypertension, or are on anti-platelet medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could enhance platelet function and reduce complications associated with sickle cell anemia.
How similar studies have performed: While MitoQ has been studied in other conditions, this specific application in sickle cell anemia is novel and has not been previously tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Subjects * African American * Patients with sickle cell anemia * 18 years old or older Control * African American healthy controls * 18 years of age or older Exclusion Criteria: 1. Pregnancy, 2. Known hypertension, 3. Hemodialysis and active obstructive sleep apnea requiring treatment. 4. Use of anti-platelet medication or have had transfusion in the 4 weeks prior to enrollment.
Where this trial is running
Pittsburgh, Pennsylvania and 4 other locations
- Magee Women's Hospital — Pittsburgh, Pennsylvania, United States (Recruiting)
- UPMC Montefiore — Pittsburgh, Pennsylvania, United States (Recruiting)
- UPMC Presbyterian — Pittsburgh, Pennsylvania, United States (Recruiting)
- Children's Hospital of Pittsburgh — Pittsburgh, Pennsylvania, United States (Recruiting)
- Hillman Cancer Center — Pittsburgh, Pennsylvania, United States (Recruiting)
Study contacts
- Principal investigator: Ramasubramanian Kalpatthi, MD — University of Pittsburgh
- Study coordinator: Mikhil N Bamne, PhD
- Email: bamnemn2@upmc.edu
- Phone: (412) 648-6920
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.